Viridian Therapeutics Plans Two Late-Stage Trials of VRDN-003 in Thyroid Eye Disease -- Shares Advance Premarket

MT Newswires Live06-11

Viridian Therapeutics (VRDN) said Tuesday that it will begin two late-stage clinical trials to evaluate VRDN-003 in patients with active and chronic thyroid eye disease in August.

The trials will assess two active dosing regimens of VRDN-003, both with a primary endpoint of proptosis responder rate compared with placebo, said Viridian Therapeutics. Topline data from the trials are expected in the first half of 2026, with the company aiming to file a biologics license application for VRDN-003 by the end of 2026.

Shares of Viridian Therapeutics were up more than 12% in recent Tuesday premarket activity.

Price: 13.76, Change: +1.54, Percent Change: +12.60

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2442136418?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-06-11 19:24","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2442136418","market":"sh","top_or_hot":-1,"title":"Viridian Therapeutics Plans Two Late-Stage Trials of VRDN-003 in Thyroid Eye Disease -- Shares Advance Premarket","media":"MT Newswires Live","content":"<html><body><p> Viridian <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> (VRDN) said Tuesday that it will begin two late-stage clinical trials to evaluate VRDN-003 in patients with active and chronic thyroid eye disease in August. </p><p>The trials will assess two active dosing regimens of VRDN-003, both with a primary endpoint of proptosis responder rate compared with placebo, said Viridian Therapeutics. Topline data from the trials are expected in the first half of 2026, with the company aiming to file a biologics license application for VRDN-003 by the end of 2026.</p><p>Shares of Viridian Therapeutics were up more than 12% in recent Tuesday premarket activity.</p><p>Price: 13.76, Change: +1.54, Percent Change: +12.60</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Viridian Therapeutics Plans Two Late-Stage Trials of VRDN-003 in Thyroid Eye Disease -- Shares Advance Premarket</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nViridian Therapeutics Plans Two Late-Stage Trials of VRDN-003 in Thyroid Eye Disease -- Shares Advance Premarket\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-06-11 19:24 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.mtnewswires.com/><strong>MT Newswires Live</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Viridian Therapeutics (VRDN) said Tuesday that it will begin two late-stage clinical trials to evaluate VRDN-003 in patients with active and chronic thyroid eye disease in August. The trials will ...</p>\n\n<a href=\"https://www.mtnewswires.com/\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"VRDN","symbol_name":"Viridian Therapeutics, Inc.","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2442136418","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2442136418","pubTimestamp":1718105099,"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Viridian Therapeutics  said Tuesday that it will begin two late-stage clinical trials to evaluate VRDN-003 in patients with active and chronic thyroid eye disease in August. The trials will assess two active dosing regimens of VRDN-003, both with a primary endpoint of proptosis responder rate compared with placebo, said Viridian Therapeutics. Topline data from the trials are expected in the first half of 2026, with the company aiming to file a biologics license application for VRDN-003 by the end of 2026.Shares of Viridian Therapeutics were up more than 12% in recent Tuesday premarket activity.Price: 13.76, Change: +1.54, Percent Change: +12.60","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"VRDN":"Viridian Therapeutics, Inc.","BK4139":"生物科技","SSI":"Stage Stores Inc"},"translate_title":"Viridian Therapeutics计划对VRDN-003进行两项治疗甲状腺眼病的后期试验——股价提前上市","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"SSI":1,"VRDN":1},"content_text":"Viridian Therapeutics (VRDN) said Tuesday that it will begin two late-stage clinical trials to evaluate VRDN-003 in patients with active and chronic thyroid eye disease in August. The trials will assess two active dosing regimens of VRDN-003, both with a primary endpoint of proptosis responder rate compared with placebo, said Viridian Therapeutics. Topline data from the trials are expected in the first half of 2026, with the company aiming to file a biologics license application for VRDN-003 by the end of 2026.Shares of Viridian Therapeutics were up more than 12% in recent Tuesday premarket activity.Price: 13.76, Change: +1.54, Percent Change: +12.60","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":null,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.24.2","shortVersion":"4.24.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2442136418"}